Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
415 Capital
AddedFeb 15, 2024
UpdatedJun 28, 2026
415 Capital

415 Capital

Operating

415 CAPITAL: A venture capital firm investing in innovative MedTech companies, focusing on cardiovascular solutions.

Location
Oberhaching, Bavaria, DE
Founded
2018
Firm
Compare
Portfolio
Employees
Website

415 Capital is a specialist venture capital firm focusing on early- and development-stage MedTech companies in Europe, the United States, and Israel. Their primary investment focus is on innovative medical device technologies addressing cardiovascular disease, recognizing it as a leading global health concern and major healthcare cost driver. Typical investments span from seed to Series D rounds.

The firm boasts a strong track record, having funded over 45 MedTech companies and achieved multiple successful exits through trade sales and IPOs. 415 Capital offers portfolio companies not only capital but also clinical, scientific, and business expertise, along with market access. Notable investments include Moray Medical, R3 Vascular, and Supira Medical, demonstrating their commitment to funding breakthrough medical innovations.

415 Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments7
Current Portfolio Count4
Total Portfolio Exits0

Top Investment Stages

Series B2 (28.6%)
Series C2 (28.6%)
Seed1 (14.3%)
Series A1 (14.3%)
Series D1 (14.3%)

Stage Mix

Series B 29%Series C 29%Seed 14%Series A 14%Series D 14%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Endovascular Engineering logo

Endovascular Engineering

Supira Medical logo

Supira Medical

Moray Medical logo

Moray Medical

R3 Vascular logo

R3 Vascular

415 Capital - Similar Investment Firms

415 logo

415

5150 Capital logo

5150 Capital

5150capital.com

1315 Capital logo

1315 Capital

1315capital.com

PA MedTech VC Fund logo

PA MedTech VC Fund

MedVenture logo

MedVenture

medventure.vc

Medingenii Capital logo

Medingenii Capital

medingenii.com

Longitude Capital logo

Longitude Capital

FiveT Fintech logo

FiveT Fintech

fivet.com

T5 Capital logo

T5 Capital

42Cap logo

42Cap

468 Capital logo

468 Capital

468cap.com

Heal Capital logo

Heal Capital

healcapital.com

Capitana Venture Partners logo

Capitana Venture Partners

Capri Ventures logo

Capri Ventures

capriventures.com

4Bio Capital logo

4Bio Capital

4biocapital.com

415 Capital - Classification

Also Known As
  • 415 Capital Management Gmbh
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end